Intelligence Platform

Patents

Browse 248 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 9925182

Compositions, dosage forms, and co-administration of an opioid agonist compound and an ana

Nektar Therapeutics · Granted Tue Mar 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9914763

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9878046

Adverse side-effects associated with administration of an anti-hyaluronan agent and method

HALOZYME, INC. · Granted Tue Jan 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9878031

Compositions, methods of administration and uses for trivalent dengue virus formulations

Takeda Vaccines, Inc. · Granted Tue Jan 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9849100

Pharmaceutical compositions suitable for parenteral administration comprising aqueous susp

KalVista Pharmaceuticals Limited · Granted Tue Dec 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9827223

Selective ablation of pain-sensing neurons by administration of a vanilloid receptor agoni

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Nov 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9808486

Administration of kynurenine depleting enzymes for tumor therapy

The Board of Regents of the University of Texas System · Granted Tue Nov 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9775881

Methods of treating mesothelioma by administration of compounds comprising FGFR1 ECD

Five Prime Therapeutics, Inc. · Granted Tue Oct 03 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9758761

Aligned and electrospun piezoelectric polymer fiber assembly and scaffold

The United States of America as represented by the Administrator of the National Aeronautics and Space Administration · Granted Tue Sep 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9757468

Intranasal administration of guanidinylated aminoglycosides

The Regents of the University of California · Granted Tue Sep 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9724387

Administration of growth factors for the treatment of CNS disorders

The Regents of the University of California · Granted Tue Aug 08 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 03 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9675550

Methods for inducing an immune response via buccal and/or sublingual administration of a v

The Board of Regents of the University of Texas System · Granted Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9592207

Intranasal administration of ketamine to treat depression

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9580489

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9526882

Percutaneous administration device and method for producing the same

OPTNICS PRECISION CO., LTD. · Granted Tue Dec 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9504671

Pharmaceutical compositions of spiro-oxindole compound for topical administration and thei

Xenon Pharmaceuticals Inc. · Granted Tue Nov 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9504736

Administration of serine protease inhibitors to the stomach

The Regents of the University of California · Granted Tue Nov 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9486426

Method of administration of gamma hydroxybutyrate with monocarboxylate transporters

Jazz Pharmaceuticals Ireland Limited · Granted Tue Nov 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9427578

Pharmacokinetics of iontophoretic sumatriptan administration

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Aug 30 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9358240

Treprostinil administration by inhalation

United Therapeutics Corporation · Granted Tue Jun 07 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 02 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9340594

VEGF antagonist formulations for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9339507

Treprostinil administration by inhalation

United Therapeutics Corporation · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9259456

Methods and compositions for oral administration of proteins

Oramed Pharmaceuticals Inc. · Granted Tue Feb 16 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9241934

Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropane

Vertex Pharmaceuticals Incorporated · Granted Tue Jan 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted